Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.495 +0.085 (+2.49%)
Streaming Delayed Price Updated: 3:37 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 206,466
Open 3.350
Bid (Size) 3.490 (2,000)
Ask (Size) 3.500 (800)
Prev. Close 3.410
Today's Range 3.340 - 3.510
52wk Range 2.455 - 4.020
Shares Outstanding 83,399,377
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill

Performance

YTD
+0.4%
+0.4%
1 Month
+9.2%
+9.2%
3 Month
+17.7%
+17.7%
6 Month
-4.4%
-4.4%
1 Year
+2.8%
+2.8%

More News

Read More
News headline image
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharma (AVIR) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update ↗
Via Chartmill
News headline image
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Earnings Preview ↗
Via Benzinga
News headline image
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea (AVIR) Q2 Loss Narrows 8% ↗
Via The Motley Fool
News headline image
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Top movers in Wednesday's pre-market session ↗
Via Chartmill

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Atea Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Atea Pharmaceuticals, Inc. - common stock trade on?
Atea Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atea Pharmaceuticals, Inc. - common stock?
The ticker symbol for Atea Pharmaceuticals, Inc. - common stock is AVIR on the Nasdaq Stock Market
What is the current price of Atea Pharmaceuticals, Inc. - common stock?
The current price of Atea Pharmaceuticals, Inc. - common stock is 3.495
When was Atea Pharmaceuticals, Inc. - common stock last traded?
The last trade of Atea Pharmaceuticals, Inc. - common stock was at 01/07/26 03:37 PM ET
What is the market capitalization of Atea Pharmaceuticals, Inc. - common stock?
The market capitalization of Atea Pharmaceuticals, Inc. - common stock is 291.48M
How many shares of Atea Pharmaceuticals, Inc. - common stock are outstanding?
Atea Pharmaceuticals, Inc. - common stock has 291M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.